Switch theme
Sign up to access all valuation multiples
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
2007
127
LTM Revenue $2.2M
LTM EBITDA -$18.1M
$28.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Q-linea has a last 12-month revenue (LTM) of $2.2M and a last 12-month EBITDA of -$18.1M.
In the most recent fiscal year, Q-linea achieved revenue of $0.2M and an EBITDA of -$20.2M.
Q-linea expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Q-linea valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $1.3M | XXX | -$1.1M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | -470% | XXX | XXX | XXX |
| EBITDA | -$18.1M | XXX | -$20.2M | XXX | XXX | XXX |
| EBITDA Margin | -807% | XXX | -8273% | XXX | XXX | XXX |
| EBIT | -$19.9M | XXX | -$22.0M | XXX | XXX | XXX |
| EBIT Margin | -888% | XXX | -9045% | XXX | XXX | XXX |
| Net Profit | -$20.2M | XXX | -$22.4M | XXX | XXX | XXX |
| Net Margin | -903% | XXX | -9182% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $11.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Q-linea's stock price is SEK 0 (or $0).
Q-linea has current market cap of SEK 296M (or $30.6M), and EV of SEK 279M (or $28.8M).
See Q-linea trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.8M | $30.6M | XXX | XXX | XXX | XXX | $-0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Q-linea has market cap of $30.6M and EV of $28.8M.
Q-linea's trades at 118.3x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Q-linea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Q-linea has a P/E ratio of -1.5x.
See valuation multiples for Q-linea and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $30.6M | XXX | $30.6M | XXX | XXX | XXX |
| EV (current) | $28.8M | XXX | $28.8M | XXX | XXX | XXX |
| EV/Revenue | 12.9x | XXX | 118.3x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 22.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | -1.6x | XXX | -1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQ-linea's last 12 month revenue growth is 261%
Q-linea's revenue per employee in the last FY averaged $2K, while opex per employee averaged $0.2M for the same period.
Q-linea's rule of 40 is -4475% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Q-linea's rule of X is -155% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Q-linea and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 261% | XXX | 633% | XXX | XXX | XXX |
| EBITDA Margin | -807% | XXX | -8273% | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -4475% | XXX | -8012% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -155% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8574% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Q-linea acquired XXX companies to date.
Last acquisition by Q-linea was XXXXXXXX, XXXXX XXXXX XXXXXX . Q-linea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Q-linea founded? | Q-linea was founded in 2007. |
| Where is Q-linea headquartered? | Q-linea is headquartered in Sweden. |
| How many employees does Q-linea have? | As of today, Q-linea has 127 employees. |
| Who is the CEO of Q-linea? | Q-linea's CEO is Mr. Stuart Gander. |
| Is Q-linea publicy listed? | Yes, Q-linea is a public company listed on STO. |
| What is the stock symbol of Q-linea? | Q-linea trades under QLINEA ticker. |
| When did Q-linea go public? | Q-linea went public in 2018. |
| Who are competitors of Q-linea? | Similar companies to Q-linea include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Q-linea? | Q-linea's current market cap is $30.6M |
| What is the current revenue of Q-linea? | Q-linea's last 12 months revenue is $2.2M. |
| What is the current revenue growth of Q-linea? | Q-linea revenue growth (NTM/LTM) is 261%. |
| What is the current EV/Revenue multiple of Q-linea? | Current revenue multiple of Q-linea is 12.9x. |
| Is Q-linea profitable? | Yes, Q-linea is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Q-linea? | Q-linea's last 12 months EBITDA is -$18.1M. |
| What is Q-linea's EBITDA margin? | Q-linea's last 12 months EBITDA margin is -807%. |
| What is the current EV/EBITDA multiple of Q-linea? | Current EBITDA multiple of Q-linea is -1.6x. |
| What is the current FCF of Q-linea? | Q-linea's last 12 months FCF is -$17.7M. |
| What is Q-linea's FCF margin? | Q-linea's last 12 months FCF margin is -790%. |
| What is the current EV/FCF multiple of Q-linea? | Current FCF multiple of Q-linea is -1.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
